Longitudinal Assessment of Physical Activity, Fitness, Body Composition, Immunological Biomarkers, and Psychological Parameters During the First Year After Diagnosis in Women With Non-Metastatic Breast Cancer: The BEGYN Study Protocol.
body composition
breast cancer
chemotherapy
immune monitoring
observational study
physical activity
psychological parameters
spiroergometry
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
22
08
2021
accepted:
01
10
2021
entrez:
5
11
2021
pubmed:
6
11
2021
medline:
6
11
2021
Statut:
epublish
Résumé
Moderate physical activity is associated with an improved prognosis and psychosocial outcome in breast cancer patients. Although exercise and physical activity are associated with multiple physiological and psychological effects, many of the underlying mechanisms remain obscure. The BEGYN study (Influence of physical activity in breast cancer patients on physiological and psychological parameters and on biomarkers) aims at identifying potential associations between the extent of physical activity, fitness, body composition, immunological biomarkers, psycho-emotional parameters, and the course of treatment during the first year after diagnosis of breast cancer. The prospective observational BEGYN study will include 110 non-metastatic breast cancer patients. The patients will be assessed during a base line visit prior to the initiation of the antineoplastic therapy and after 3, 6, 9 and 12 months. The physical activity will be measured using a fitness tracker and a self-assessment diary during the entire study. Each visit will include the assessment of (i) cardiorespiratory fitness measured by spiroergometry, (ii) body composition, (iii) psycho-emotional parameters (quality of life, mental health, fatigue, depression, distress, anxiety, well-being), and (iv) extensive blood tests including routine laboratory, vitamin D, selenium and immunologically relevant biomarkers (e.g., leukocyte subpopulations and cytokine profiles). Whereas most studies investigating the influence of physical activity in breast cancer patients focus on specific activities for three months or less, the BEGYN study will quantify the daily physical activity and cardiorespiratory fitness of breast cancer patients based on objective measurements in the context of the oncological therapy for 12 months after diagnosis. The study will reveal potential associations between exercise, immune status and physical as well as psycho-emotional outcome and the clinical course of the disease. Moreover, complementary therapies such as Vit D and Selenium supplementation and parameters investigating the motivation of the patients are part of the study. Due to this holistic approach, the BEGYN study will guide towards confirmatory studies on the role of physical activity in breast cancer patients to develop individualized counselling regarding the recommended type and extent of exercise. This study has been registered at the German Clinical Trials Register DRKS00024829.
Sections du résumé
BACKGROUND
BACKGROUND
Moderate physical activity is associated with an improved prognosis and psychosocial outcome in breast cancer patients. Although exercise and physical activity are associated with multiple physiological and psychological effects, many of the underlying mechanisms remain obscure. The BEGYN study (Influence of physical activity in breast cancer patients on physiological and psychological parameters and on biomarkers) aims at identifying potential associations between the extent of physical activity, fitness, body composition, immunological biomarkers, psycho-emotional parameters, and the course of treatment during the first year after diagnosis of breast cancer.
METHODS
METHODS
The prospective observational BEGYN study will include 110 non-metastatic breast cancer patients. The patients will be assessed during a base line visit prior to the initiation of the antineoplastic therapy and after 3, 6, 9 and 12 months. The physical activity will be measured using a fitness tracker and a self-assessment diary during the entire study. Each visit will include the assessment of (i) cardiorespiratory fitness measured by spiroergometry, (ii) body composition, (iii) psycho-emotional parameters (quality of life, mental health, fatigue, depression, distress, anxiety, well-being), and (iv) extensive blood tests including routine laboratory, vitamin D, selenium and immunologically relevant biomarkers (e.g., leukocyte subpopulations and cytokine profiles).
DISCUSSION
CONCLUSIONS
Whereas most studies investigating the influence of physical activity in breast cancer patients focus on specific activities for three months or less, the BEGYN study will quantify the daily physical activity and cardiorespiratory fitness of breast cancer patients based on objective measurements in the context of the oncological therapy for 12 months after diagnosis. The study will reveal potential associations between exercise, immune status and physical as well as psycho-emotional outcome and the clinical course of the disease. Moreover, complementary therapies such as Vit D and Selenium supplementation and parameters investigating the motivation of the patients are part of the study. Due to this holistic approach, the BEGYN study will guide towards confirmatory studies on the role of physical activity in breast cancer patients to develop individualized counselling regarding the recommended type and extent of exercise.
TRIAL REGISTRATION
BACKGROUND
This study has been registered at the German Clinical Trials Register DRKS00024829.
Identifiants
pubmed: 34737966
doi: 10.3389/fonc.2021.762709
pmc: PMC8560964
doi:
Types de publication
Journal Article
Langues
eng
Pagination
762709Informations de copyright
Copyright © 2021 Zemlin, Stuhlert, Schleicher, Wörmann, Altmayer, Lang, Scherer, Thul, Müller, Kaiser, Stutz, Goedicke-Fritz, Ketter, Zemlin, Wagenpfeil, Steffgen and Solomayer.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
N Engl J Med. 2009 Aug 13;361(7):664-73
pubmed: 19675330
Front Nutr. 2020 Oct 08;7:557997
pubmed: 33134306
Ann Hematol. 2021 Feb;100(2):445-453
pubmed: 33140135
Eur J Endocrinol. 2007 Jun;156(6):655-61
pubmed: 17535865
Breast Cancer. 2018 May;25(3):284-291
pubmed: 29204848
BMC Public Health. 2016 Jun 16;16:515
pubmed: 27306667
Scand J Med Sci Sports. 2018 Aug;28 Suppl 1:61-73
pubmed: 30001572
JCI Insight. 2020 Feb 27;5(4):
pubmed: 32102986
Mol Cell Biochem. 2015 Jan;398(1-2):245-9
pubmed: 25292313
PLoS One. 2018 Aug 1;13(8):e0200061
pubmed: 30067754
Cancer Res. 2019 Sep 15;79(18):4557-4566
pubmed: 31350295
Med Sci Sports Exerc. 2011 Aug;43(8):1575-81
pubmed: 21681120
Exp Gerontol. 2021 Sep;152:111454
pubmed: 34146655
Anticancer Agents Med Chem. 2021 Jun 08;:
pubmed: 34151769
Proc Nutr Soc. 2018 Nov;77(4):382-387
pubmed: 29860952
Cancer. 1998 May 15;82(10):1904-8
pubmed: 9587123
J Clin Oncol. 2009 Mar 10;27(8):1197-201
pubmed: 19164208
J Pain Symptom Manage. 1997 Feb;13(2):63-74
pubmed: 9095563
J Clin Oncol. 2014 Nov 1;32(31):3540-6
pubmed: 25287821
Cochrane Database Syst Rev. 2016 Sep 21;9:CD005001
pubmed: 27650122
Breast Care (Basel). 2020 Jun;15(3):236-245
pubmed: 32774217
Psychooncology. 2011 Feb;20(2):115-26
pubmed: 20336645
Genes Dev. 2018 Oct 1;32(19-20):1267-1284
pubmed: 30275043
J Cancer Res Ther. 2017 Jul-Sep;13(3):392-398
pubmed: 28862198
Ann Oncol. 2013 Feb;24(2):291-300
pubmed: 23041586
Support Care Cancer. 2018 Mar;26(3):861-868
pubmed: 28948392
PLoS One. 2020 Jul 24;15(7):e0236323
pubmed: 32706814
J Clin Oncol. 2014 Oct 10;32(29):3242-8
pubmed: 25135997
Int J Cancer. 2015 Jul 15;137(2):471-80
pubmed: 25484317
Arch Gynecol Obstet. 2019 Jul;300(1):201-206
pubmed: 31044301
Curr Sports Med Rep. 2009 Jul-Aug;8(4):176-81
pubmed: 19584603
Front Oncol. 2019 Sep 25;9:962
pubmed: 31612110
Cochrane Database Syst Rev. 2018 Jan 29;1:CD005195
pubmed: 29376219
Med Sci Sports Exerc. 1980;12(3):175-81
pubmed: 7402053
Front Oncol. 2020 Apr 23;10:607
pubmed: 32391277
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Clin Med. 2018 Dec 01;7(12):
pubmed: 30513777
Int J Biol Sci. 2011;7(5):651-8
pubmed: 21647333
J Clin Oncol. 2018 Sep 1;36(25):2647-2655
pubmed: 29889605
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Front Oncol. 2020 Oct 21;10:556718
pubmed: 33194622
Support Care Cancer. 2017 Apr;25(4):1047-1054
pubmed: 27942857
Curr Oncol. 2017 Aug;24(4):e290-e315
pubmed: 28874900
Cochrane Database Syst Rev. 2012 Nov 14;11:CD006145
pubmed: 23152233
Front Oncol. 2020 Apr 02;10:422
pubmed: 32300557
Breast Cancer Res Treat. 2018 Feb;168(1):147-157
pubmed: 29168064
Complement Ther Med. 2019 Dec;47:102197
pubmed: 31780003
Breast. 2015 Apr;24(2):166-70
pubmed: 25623753
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Semin Radiat Oncol. 2019 Jan;29(1):16-24
pubmed: 30573180
Br J Cancer. 2017 Apr 11;116(8):1092-1110
pubmed: 28301870
EBioMedicine. 2020 Feb;52:102631
pubmed: 31981982
Crit Rev Oncol Hematol. 2013 Dec;88(3):573-93
pubmed: 23932804
Curr Opin Pharmacol. 2021 Apr;57:148-156
pubmed: 33735662
PLoS One. 2020 Dec 4;15(12):e0238010
pubmed: 33275613
Sports Med. 2017 Sep;47(9):1821-1845
pubmed: 28303543
Scand J Work Environ Health. 1990;16 Suppl 1:55-8
pubmed: 2345867
J Sci Med Sport. 2020 Mar;23(3):283-290
pubmed: 31640924
Nutrition. 2021 Jul 30;93:111442
pubmed: 34482097
J Pers Med. 2021 Jul 20;11(7):
pubmed: 34357148
Sensors (Basel). 2014 Jun 19;14(6):10895-928
pubmed: 24949644
BMC Womens Health. 2021 Aug 11;21(1):297
pubmed: 34380488
Sports (Basel). 2021 Mar 30;9(4):
pubmed: 33808154
Cell. 1997 May 16;89(4):587-96
pubmed: 9160750
Breast Care (Basel). 2018 Oct;13(5):380-385
pubmed: 30498426
J Cancer Res Clin Oncol. 2018 Mar;144(3):579-586
pubmed: 29305709
Curr Pain Headache Rep. 2014 Mar;18(3):399
pubmed: 24500637
Front Oncol. 2020 Aug 07;10:1304
pubmed: 32903594
Clin Hemorheol Microcirc. 2017;67(3-4):221-227
pubmed: 28885197
J Affect Disord. 2020 Aug 1;273:210-214
pubmed: 32421605
Eur J Immunol. 2017 Oct;47(10):1584-1797
pubmed: 29023707
Int J Mol Sci. 2020 May 27;21(11):
pubmed: 32471301
Breast Cancer Res Treat. 2018 Jul;170(1):1-13
pubmed: 29470804
Dtsch Arztebl Int. 2018 Jun 15;115(24):409-416
pubmed: 29968559
Oncoimmunology. 2018 Nov 5;8(2):e1537691
pubmed: 30713794
Physiol Behav. 2018 Oct 1;194:260-267
pubmed: 29885920
Front Mol Biosci. 2021 May 28;8:673051
pubmed: 34124156
Int J Med Sci. 2015 Jan 01;12(1):7-16
pubmed: 25552913
J Clin Oncol. 2014 Jun 10;32(17):1840-50
pubmed: 24733803
Science. 2005 Jan 21;307(5708):430-3
pubmed: 15662016
Cochrane Database Syst Rev. 2012 Aug 15;(8):CD008465
pubmed: 22895974
Front Oncol. 2018 Jan 11;7:326
pubmed: 29376027
Breast Care (Basel). 2018 Apr;13(2):93-101
pubmed: 29887785
J Natl Cancer Inst. 2021 Jan 4;113(1):54-63
pubmed: 32239145
Med Sci Sports Exerc. 2003 Sep;35(9):1596-603
pubmed: 12972882
Nat Commun. 2012;3:1268
pubmed: 23232398
J Natl Compr Canc Netw. 2019 Oct 1;17(10):1229-1249
pubmed: 31590149
Int J Sports Med. 2011 Jun;32(6):461-7
pubmed: 21380980
Lancet Oncol. 2003 Oct;4(10):616-25
pubmed: 14554239
Disabil Rehabil. 2018 Feb;40(4):486-496
pubmed: 28054496
Clin J Oncol Nurs. 2008 Oct;12(5 Suppl):21-5
pubmed: 18842521
Cell Mol Immunol. 2021 Mar;18(3):604-612
pubmed: 33060840
Front Immunol. 2017 Nov 16;8:1543
pubmed: 29201026